MIRA

Mira Pharmaceuticals, Inc. develops novel oral therapies targeting neurologic, inflammatory, and metabolic diseases. The company focuses on reengineering proven biological mechanisms into safer, orally available treatments. Its lead program, Ketamir-2, is advancing toward Phase 2a clinical trials for chemotherapy-induced peripheral neuropathy (CIPN), while other programs, such as MIRA-55 and SKNY-1, are in various stages of development for chronic inflammatory pain and obesity/nicotine addiction, respectively.